With over 30 years in the pharmaceutical and diagnostic sectors in roles spanning sales, marketing, and market access, I bring a wealth of industry experience. Currently, as an independent consultant, I collaborate with several functional precision medicine (FPM) diagnostic companies. Previously, I served as the VP of Market Access at Kiyatec.
I joined SFPM in the spring of 2022 and was instrumental in establishing the Regulatory and Reimbursement Workgroup. Our group is actively advocating for the Center for Medicare and Medicaid Services (CMS) to retire the National Coverage Determination (NCD) 190.7, an outdated policy that hinders the progress of chemosensitivity tests and, by extension, our collective efforts to enhance cancer care through functional testing.
I am committed to leveraging my expertise to advance SFPM's mission and improve access to FPM testing for cancer patients. Thank you for considering my candidacy. I look forward to the opportunity to contribute more significantly to our shared goals.